Similar articles

• Ethics and FDA.

  Fielder JH. Fielder JH. Food Drug Law J. 2006;61(4):809-10. Food Drug Law J. 2006. PMID: 17180775 No abstract available.
• Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.

  Wang Y, Bhattaram AV, Jadhav PR, Lesko LJ, Madabushi R, Powell JR, Qiu W, Sun H, Yim DS, Zheng JJ, Gobburu JV. Wang Y, et al. J Clin Pharmacol. 2008 Feb;48(2):146-56. doi: 10.1177/0091270007311111. J Clin Pharmacol. 2008. PMID: 18199891
• The process of drug decision making: perspectives of an FDA Commissioner.

  Hayes AH Jr. Hayes AH Jr. Hosp Formul. 1985 Aug;20(8):896-900. Hosp Formul. 1985. PMID: 10272396
• One hundred years of drug regulation: where do we go from here?

  Woosley RL. Woosley RL. Annu Rev Pharmacol Toxicol. 2013;53:255-73. doi: 10.1146/annurev-pharmtox-011112-140159. Epub 2012 Oct 16. Annu Rev Pharmacol Toxicol. 2013. PMID: 23072378 Review.
• Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective.

  Schwieterman WD. Schwieterman WD. Drug Discov Today. 2006 Oct;11(19-20):945-51. doi: 10.1016/j.drudis.2006.08.011. Epub 2006 Sep 7. Drug Discov Today. 2006. PMID: 16997146 Review.